-
1
-
-
0013394889
-
Mechanisms of alternative pre-messenger RNA splicing
-
Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 72 (2003) 291-336
-
(2003)
Annu. Rev. Biochem.
, vol.72
, pp. 291-336
-
-
Black, D.L.1
-
2
-
-
18344364099
-
Understanding alternative splicing: towards a cellular code
-
Matlin A.J., Clark F., and Smith C.W. Understanding alternative splicing: towards a cellular code. Nat. Rev., Mol. Cell Biol. 6 (2005) 386-398
-
(2005)
Nat. Rev., Mol. Cell Biol.
, vol.6
, pp. 386-398
-
-
Matlin, A.J.1
Clark, F.2
Smith, C.W.3
-
3
-
-
33746927884
-
The connection between splicing and cancer
-
Srebrow A., and Kornblihtt A.R. The connection between splicing and cancer. J. Cell Sci. 119 (2006) 2635-2641
-
(2006)
J. Cell Sci.
, vol.119
, pp. 2635-2641
-
-
Srebrow, A.1
Kornblihtt, A.R.2
-
4
-
-
0036534129
-
Alternative splicing: multiple control mechanisms and involvement in human disease
-
Caceres J.F., and Kornblihtt A.R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18 (2002) 186-193
-
(2002)
Trends Genet.
, vol.18
, pp. 186-193
-
-
Caceres, J.F.1
Kornblihtt, A.R.2
-
5
-
-
0037443035
-
Pre-mRNA splicing and human disease
-
Faustino N.A., and Cooper T.A. Pre-mRNA splicing and human disease. Genes Dev. 17 (2003) 419-437
-
(2003)
Genes Dev.
, vol.17
, pp. 419-437
-
-
Faustino, N.A.1
Cooper, T.A.2
-
7
-
-
33947541694
-
Alternative splicing: an emerging topic in molecular and clinical oncology
-
Pajares M.J., Ezponda T., Catena R., Calvo A., Pio R., and Montuenga L.M. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol. 8 (2007) 349-357
-
(2007)
Lancet Oncol.
, vol.8
, pp. 349-357
-
-
Pajares, M.J.1
Ezponda, T.2
Catena, R.3
Calvo, A.4
Pio, R.5
Montuenga, L.M.6
-
8
-
-
7444220147
-
Aberrant and alternative splicing in cancer
-
Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res. 64 (2004) 7647-7654
-
(2004)
Cancer Res.
, vol.64
, pp. 7647-7654
-
-
Venables, J.P.1
-
9
-
-
13944252065
-
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk
-
Narla G., Difeo A., Reeves H.L., Schaid D.J., Hirshfeld J., Hod E., Katz A., Isaacs W.B., Hebbring S., Komiya A., McDonnell S.K., Wiley K.E., Jacobsen S.J., Isaacs S.D., Walsh P.C., Zheng S.L., Chang B.L., Friedrichsen D.M., Stanford J.L., Ostrander E.A., Chinnaiyan A.M., Rubin M.A., Xu J., Thibodeau S.N., Friedman S.L., and Martignetti J.A. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65 (2005) 1213-1222
-
(2005)
Cancer Res.
, vol.65
, pp. 1213-1222
-
-
Narla, G.1
Difeo, A.2
Reeves, H.L.3
Schaid, D.J.4
Hirshfeld, J.5
Hod, E.6
Katz, A.7
Isaacs, W.B.8
Hebbring, S.9
Komiya, A.10
McDonnell, S.K.11
Wiley, K.E.12
Jacobsen, S.J.13
Isaacs, S.D.14
Walsh, P.C.15
Zheng, S.L.16
Chang, B.L.17
Friedrichsen, D.M.18
Stanford, J.L.19
Ostrander, E.A.20
Chinnaiyan, A.M.21
Rubin, M.A.22
Xu, J.23
Thibodeau, S.N.24
Friedman, S.L.25
Martignetti, J.A.26
more..
-
10
-
-
0034326802
-
Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation
-
Ahn J.Y., Schwarz J.K., Piwnica-Worms H., and Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60 (2000) 5934-5936
-
(2000)
Cancer Res.
, vol.60
, pp. 5934-5936
-
-
Ahn, J.Y.1
Schwarz, J.K.2
Piwnica-Worms, H.3
Canman, C.E.4
-
11
-
-
0036258583
-
Chk2 activation and phosphorylation-dependent oligomerization
-
Xu X., Tsvetkov L.M., and Stern D.F. Chk2 activation and phosphorylation-dependent oligomerization. Mol. Cell. Biol. 22 (2002) 4419-4432
-
(2002)
Mol. Cell. Biol.
, vol.22
, pp. 4419-4432
-
-
Xu, X.1
Tsvetkov, L.M.2
Stern, D.F.3
-
12
-
-
0035839526
-
The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation
-
Lee C.H., and Chung J.H. The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J. Biol. Chem. 276 (2001) 30537-30541
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 30537-30541
-
-
Lee, C.H.1
Chung, J.H.2
-
13
-
-
0037795780
-
Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation
-
Schwarz J.K., Lovly C.M., and Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res. 1 (2003) 598-609
-
(2003)
Mol. Cancer Res.
, vol.1
, pp. 598-609
-
-
Schwarz, J.K.1
Lovly, C.M.2
Piwnica-Worms, H.3
-
14
-
-
0035848819
-
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
-
Falck J., Mailand N., Syljuasen R.G., Bartek J., and Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410 (2001) 842-847
-
(2001)
Nature
, vol.410
, pp. 842-847
-
-
Falck, J.1
Mailand, N.2
Syljuasen, R.G.3
Bartek, J.4
Lukas, J.5
-
15
-
-
0033552873
-
A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase
-
Blasina A., de Weyer I.V., Laus M.C., Luyten W.H., Parker A.E., and McGowan C.H. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol. 9 (1999) 1-10
-
(1999)
Curr. Biol.
, vol.9
, pp. 1-10
-
-
Blasina, A.1
de Weyer, I.V.2
Laus, M.C.3
Luyten, W.H.4
Parker, A.E.5
McGowan, C.H.6
-
16
-
-
0032484084
-
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
-
Matsuoka S., Huang M., and Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 (1998) 1893-1897
-
(1998)
Science
, vol.282
, pp. 1893-1897
-
-
Matsuoka, S.1
Huang, M.2
Elledge, S.J.3
-
17
-
-
0034142034
-
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
-
Shieh S.Y., Ahn J., Tamai K., Taya Y., and Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14 (2000) 289-300
-
(2000)
Genes Dev.
, vol.14
, pp. 289-300
-
-
Shieh, S.Y.1
Ahn, J.2
Tamai, K.3
Taya, Y.4
Prives, C.5
-
19
-
-
0034142325
-
Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53
-
Chehab N.H., Malikzay A., Appel M., and Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14 (2000) 278-288
-
(2000)
Genes Dev.
, vol.14
, pp. 278-288
-
-
Chehab, N.H.1
Malikzay, A.2
Appel, M.3
Halazonetis, T.D.4
-
20
-
-
9144232488
-
Alternative splicing and mutation status of CHEK2 in stage III breast cancer
-
Staalesen V., Falck J., Geisler S., Bartkova J., Borresen-Dale A.L., Lukas J., Lillehaug J.R., Bartek J., and Lonning P.E. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 23 (2004) 8535-8544
-
(2004)
Oncogene
, vol.23
, pp. 8535-8544
-
-
Staalesen, V.1
Falck, J.2
Geisler, S.3
Bartkova, J.4
Borresen-Dale, A.L.5
Lukas, J.6
Lillehaug, J.R.7
Bartek, J.8
Lonning, P.E.9
-
21
-
-
52449116207
-
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer
-
Chrisanthar R., Knappskog S., Lokkevik E., Anker G., Ostenstad B., Lundgren S., Berge E.O., Risberg T., Mjaaland I., Maehle L., Engebretsen L.F., Lillehaug J.R., and Lonning P.E. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS ONE 3 (2008) e3062
-
(2008)
PLoS ONE
, vol.3
-
-
Chrisanthar, R.1
Knappskog, S.2
Lokkevik, E.3
Anker, G.4
Ostenstad, B.5
Lundgren, S.6
Berge, E.O.7
Risberg, T.8
Mjaaland, I.9
Maehle, L.10
Engebretsen, L.F.11
Lillehaug, J.R.12
Lonning, P.E.13
-
22
-
-
0035866772
-
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
-
Geisler S., Lonning P.E., Aas T., Johnsen H., Fluge O., Haugen D.F., Lillehaug J.R., Akslen L.A., and Borresen-Dale A.L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61 (2001) 2505-2512
-
(2001)
Cancer Res.
, vol.61
, pp. 2505-2512
-
-
Geisler, S.1
Lonning, P.E.2
Aas, T.3
Johnsen, H.4
Fluge, O.5
Haugen, D.F.6
Lillehaug, J.R.7
Akslen, L.A.8
Borresen-Dale, A.L.9
-
23
-
-
0344198117
-
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer
-
Geisler S., Borresen-Dale A.L., Johnsen H., Aas T., Geisler J., Akslen L.A., Anker G., and Lonning P.E. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin. Cancer Res. 9 (2003) 5582-5588
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 5582-5588
-
-
Geisler, S.1
Borresen-Dale, A.L.2
Johnsen, H.3
Aas, T.4
Geisler, J.5
Akslen, L.A.6
Anker, G.7
Lonning, P.E.8
-
24
-
-
0038054343
-
The Chk2 tumor suppressor is not required for p53 responses in human cancer cells
-
Jallepalli P.V., Lengauer C., Vogelstein B., and Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J. Biol. Chem. 278 (2003) 20475-20479
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 20475-20479
-
-
Jallepalli, P.V.1
Lengauer, C.2
Vogelstein, B.3
Bunz, F.4
-
25
-
-
15944413192
-
Identification and characterization of the human ARD1-NATH protein acetyltransferase complex
-
Arnesen T., Anderson D., Baldersheim C., Lanotte M., Varhaug J.E., and Lillehaug J.R. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem. J. 386 (2005) 433-443
-
(2005)
Biochem. J.
, vol.386
, pp. 433-443
-
-
Arnesen, T.1
Anderson, D.2
Baldersheim, C.3
Lanotte, M.4
Varhaug, J.E.5
Lillehaug, J.R.6
-
26
-
-
54049149934
-
Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a complex important for cell-cycle progression
-
Starheim K.K., Arnesen T., Gromyko D., Ryningen A., Varhaug J.E., and Lillehaug J.R. Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a complex important for cell-cycle progression. Biochem. J. 415 (2008) 325-331
-
(2008)
Biochem. J.
, vol.415
, pp. 325-331
-
-
Starheim, K.K.1
Arnesen, T.2
Gromyko, D.3
Ryningen, A.4
Varhaug, J.E.5
Lillehaug, J.R.6
-
27
-
-
0035864714
-
Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas
-
Fluge O., Haugen D.R., Akslen L.A., Marstad A., Santoro M., Fusco A., Varhaug J.E., and Lillehaug J.R. Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene 20 (2001) 885-892
-
(2001)
Oncogene
, vol.20
, pp. 885-892
-
-
Fluge, O.1
Haugen, D.R.2
Akslen, L.A.3
Marstad, A.4
Santoro, M.5
Fusco, A.6
Varhaug, J.E.7
Lillehaug, J.R.8
-
28
-
-
0035817764
-
Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway
-
Falck J., Lukas C., Protopopova M., Lukas J., Selivanova G., and Bartek J. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20 (2001) 5503-5510
-
(2001)
Oncogene
, vol.20
, pp. 5503-5510
-
-
Falck, J.1
Lukas, C.2
Protopopova, M.3
Lukas, J.4
Selivanova, G.5
Bartek, J.6
-
29
-
-
0142211234
-
Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import
-
Zannini L., Lecis D., Lisanti S., Benetti R., Buscemi G., Schneider C., and Delia D. Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import. J. Biol. Chem. 278 (2003) 42346-42351
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 42346-42351
-
-
Zannini, L.1
Lecis, D.2
Lisanti, S.3
Benetti, R.4
Buscemi, G.5
Schneider, C.6
Delia, D.7
-
30
-
-
0141704306
-
Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis
-
Wu X., and Chen J. Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis. J. Biol. Chem. 278 (2003) 36163-36168
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 36163-36168
-
-
Wu, X.1
Chen, J.2
-
31
-
-
0037205422
-
Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain
-
Ahn J.Y., Li X., Davis H.L., and Canman C.E. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J. Biol. Chem. 277 (2002) 19389-19395
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 19389-19395
-
-
Ahn, J.Y.1
Li, X.2
Davis, H.L.3
Canman, C.E.4
-
32
-
-
33746318035
-
Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange
-
Oliver A.W., Paul A., Boxall K.J., Barrie S.E., Aherne G.W., Garrett M.D., Mittnacht S., and Pearl L.H. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J. 25 (2006) 3179-3190
-
(2006)
EMBO J.
, vol.25
, pp. 3179-3190
-
-
Oliver, A.W.1
Paul, A.2
Boxall, K.J.3
Barrie, S.E.4
Aherne, G.W.5
Garrett, M.D.6
Mittnacht, S.7
Pearl, L.H.8
-
33
-
-
0033601346
-
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
-
Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C., Shannon K.E., Lubratovich M., Verselis S.J., Isselbacher K.J., Fraumeni J.F., Birch J.M., Li F.P., Garber J.E., and Haber D.A. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286 (1999) 2528-2531
-
(1999)
Science
, vol.286
, pp. 2528-2531
-
-
Bell, D.W.1
Varley, J.M.2
Szydlo, T.E.3
Kang, D.H.4
Wahrer, D.C.5
Shannon, K.E.6
Lubratovich, M.7
Verselis, S.J.8
Isselbacher, K.J.9
Fraumeni, J.F.10
Birch, J.M.11
Li, F.P.12
Garber, J.E.13
Haber, D.A.14
-
34
-
-
0035060741
-
Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome
-
Bougeard G., Limacher J.M., Martin C., Charbonnier F., Killian A., Delattre O., Longy M., Jonveaux P., Fricker J.P., Stoppa-Lyonnet D., Flaman J.M., and Frebourg T. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J. Med. Genet. 38 (2001) 253-257
-
(2001)
J. Med. Genet.
, vol.38
, pp. 253-257
-
-
Bougeard, G.1
Limacher, J.M.2
Martin, C.3
Charbonnier, F.4
Killian, A.5
Delattre, O.6
Longy, M.7
Jonveaux, P.8
Fricker, J.P.9
Stoppa-Lyonnet, D.10
Flaman, J.M.11
Frebourg, T.12
-
35
-
-
38349195014
-
Is CHEK2 a cause of the Li-Fraumeni syndrome?
-
Evans D.G., Birch J.M., and Narod S.A. Is CHEK2 a cause of the Li-Fraumeni syndrome?. J. Med. Genet. 45 (2008) 63-64
-
(2008)
J. Med. Genet.
, vol.45
, pp. 63-64
-
-
Evans, D.G.1
Birch, J.M.2
Narod, S.A.3
-
36
-
-
38349093562
-
BRCA2: a cause of Li-Fraumeni-like syndrome
-
Evans D.G., Wu C.L., and Birch J.M. BRCA2: a cause of Li-Fraumeni-like syndrome. J. Med. Genet. 45 (2008) 62-63
-
(2008)
J. Med. Genet.
, vol.45
, pp. 62-63
-
-
Evans, D.G.1
Wu, C.L.2
Birch, J.M.3
-
37
-
-
21244449269
-
The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds
-
Siddiqui R., Onel K., Facio F., Nafa K., Diaz L.R., Kauff N., Huang H., Robson M., Ellis N., and Offit K. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Fam. Cancer 4 (2005) 177-181
-
(2005)
Fam. Cancer
, vol.4
, pp. 177-181
-
-
Siddiqui, R.1
Onel, K.2
Facio, F.3
Nafa, K.4
Diaz, L.R.5
Kauff, N.6
Huang, H.7
Robson, M.8
Ellis, N.9
Offit, K.10
-
38
-
-
18744372122
-
Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome
-
Sodha N., Houlston R.S., Bullock S., Yuille M.A., Chu C., Turner G., and Eeles R.A. Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum. Mutat. 20 (2002) 460-462
-
(2002)
Hum. Mutat.
, vol.20
, pp. 460-462
-
-
Sodha, N.1
Houlston, R.S.2
Bullock, S.3
Yuille, M.A.4
Chu, C.5
Turner, G.6
Eeles, R.A.7
-
39
-
-
0034697958
-
Screening hCHK2 for mutations
-
Sodha N., Williams R., Mangion J., Bullock S.L., Yuille M.R., and Eeles R.A. Screening hCHK2 for mutations. Science 289 (2000) 359
-
(2000)
Science
, vol.289
, pp. 359
-
-
Sodha, N.1
Williams, R.2
Mangion, J.3
Bullock, S.L.4
Yuille, M.R.5
Eeles, R.A.6
-
40
-
-
0035421321
-
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition
-
Vahteristo P., Tamminen A., Karvinen P., Eerola H., Eklund C., Aaltonen L.A., Blomqvist C., Aittomaki K., and Nevanlinna H. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 61 (2001) 5718-5722
-
(2001)
Cancer Res.
, vol.61
, pp. 5718-5722
-
-
Vahteristo, P.1
Tamminen, A.2
Karvinen, P.3
Eerola, H.4
Eklund, C.5
Aaltonen, L.A.6
Blomqvist, C.7
Aittomaki, K.8
Nevanlinna, H.9
-
41
-
-
33749039966
-
The CHEK2 gene and inherited breast cancer susceptibility
-
Nevanlinna H., and Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25 (2006) 5912-5919
-
(2006)
Oncogene
, vol.25
, pp. 5912-5919
-
-
Nevanlinna, H.1
Bartek, J.2
-
42
-
-
39149141409
-
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls
-
Weischer M., Bojesen S.E., Ellervik C., Tybjaerg-Hansen A., and Nordestgaard B.G. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls. J. Clin. Oncol. 26 (2008) 542-548
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 542-548
-
-
Weischer, M.1
Bojesen, S.E.2
Ellervik, C.3
Tybjaerg-Hansen, A.4
Nordestgaard, B.G.5
-
43
-
-
3843071233
-
CHEK2 variant I157T may be associated with increased breast cancer risk
-
Kilpivaara O., Vahteristo P., Falck J., Syrjakoski K., Eerola H., Easton D., Bartkova J., Lukas J., Heikkila P., Aittomaki K., Holli K., Blomqvist C., Kallioniemi O.P., Bartek J., and Nevanlinna H. CHEK2 variant I157T may be associated with increased breast cancer risk. Int. J. Cancer 111 (2004) 543-547
-
(2004)
Int. J. Cancer
, vol.111
, pp. 543-547
-
-
Kilpivaara, O.1
Vahteristo, P.2
Falck, J.3
Syrjakoski, K.4
Eerola, H.5
Easton, D.6
Bartkova, J.7
Lukas, J.8
Heikkila, P.9
Aittomaki, K.10
Holli, K.11
Blomqvist, C.12
Kallioniemi, O.P.13
Bartek, J.14
Nevanlinna, H.15
-
44
-
-
22044445244
-
Association of two mutations in the CHEK2 gene with breast cancer
-
Bogdanova N., Enssen-Dubrowinskaja N., Feshchenko S., Lazjuk G.I., Rogov Y.I., Dammann O., Bremer M., Karstens J.H., Sohn C., and Dork T. Association of two mutations in the CHEK2 gene with breast cancer. Int. J. Cancer 116 (2005) 263-266
-
(2005)
Int. J. Cancer
, vol.116
, pp. 263-266
-
-
Bogdanova, N.1
Enssen-Dubrowinskaja, N.2
Feshchenko, S.3
Lazjuk, G.I.4
Rogov, Y.I.5
Dammann, O.6
Bremer, M.7
Karstens, J.H.8
Sohn, C.9
Dork, T.10
-
45
-
-
8844220451
-
CHEK2 is a multiorgan cancer susceptibility gene
-
Cybulski C., Gorski B., Huzarski T., Masojc B., Mierzejewski M., Debniak T., Teodorczyk U., Byrski T., Gronwald J., Matyjasik J., Zlowocka E., Lenner M., Grabowska E., Nej K., Castaneda J., Medrek K., Szymanska A., Szymanska J., Kurzawski G., Suchy J., Oszurek O., Witek A., Narod S.A., and Lubinski J. CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet. 75 (2004) 1131-1135
-
(2004)
Am. J. Hum. Genet.
, vol.75
, pp. 1131-1135
-
-
Cybulski, C.1
Gorski, B.2
Huzarski, T.3
Masojc, B.4
Mierzejewski, M.5
Debniak, T.6
Teodorczyk, U.7
Byrski, T.8
Gronwald, J.9
Matyjasik, J.10
Zlowocka, E.11
Lenner, M.12
Grabowska, E.13
Nej, K.14
Castaneda, J.15
Medrek, K.16
Szymanska, A.17
Szymanska, J.18
Kurzawski, G.19
Suchy, J.20
Oszurek, O.21
Witek, A.22
Narod, S.A.23
Lubinski, J.24
more..
-
46
-
-
33847163983
-
A deletion in CHEK2 of 5, 395 bp predisposes to breast cancer in Poland
-
Cybulski C., Wokolorczyk D., Huzarski T., Byrski T., Gronwald J., Gorski B., Debniak T., Masojc B., Jakubowska A., van de Wetering T., Narod S.A., and Lubinski J. A deletion in CHEK2 of 5, 395 bp predisposes to breast cancer in Poland. Breast Cancer Res. Treat. 102 (2007) 119-122
-
(2007)
Breast Cancer Res. Treat.
, vol.102
, pp. 119-122
-
-
Cybulski, C.1
Wokolorczyk, D.2
Huzarski, T.3
Byrski, T.4
Gronwald, J.5
Gorski, B.6
Debniak, T.7
Masojc, B.8
Jakubowska, A.9
van de Wetering, T.10
Narod, S.A.11
Lubinski, J.12
-
47
-
-
33645084562
-
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer
-
Walsh T., Casadei S., Coats K.H., Swisher E., Stray S.M., Higgins J., Roach K.C., Mandell J., Lee M.K., Ciernikova S., Foretova L., Soucek P., and King M.C. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295 (2006) 1379-1388
-
(2006)
JAMA
, vol.295
, pp. 1379-1388
-
-
Walsh, T.1
Casadei, S.2
Coats, K.H.3
Swisher, E.4
Stray, S.M.5
Higgins, J.6
Roach, K.C.7
Mandell, J.8
Lee, M.K.9
Ciernikova, S.10
Foretova, L.11
Soucek, P.12
King, M.C.13
-
48
-
-
14044272193
-
Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population
-
Shaag A., Walsh T., Renbaum P., Kirchhoff T., Nafa K., Shiovitz S., Mandell J.B., Welcsh P., Lee M.K., Ellis N., Offit K., Levy-Lahad E., and King M.C. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum. Mol. Genet. 14 (2005) 555-563
-
(2005)
Hum. Mol. Genet.
, vol.14
, pp. 555-563
-
-
Shaag, A.1
Walsh, T.2
Renbaum, P.3
Kirchhoff, T.4
Nafa, K.5
Shiovitz, S.6
Mandell, J.B.7
Welcsh, P.8
Lee, M.K.9
Ellis, N.10
Offit, K.11
Levy-Lahad, E.12
King, M.C.13
-
49
-
-
85047695017
-
Concomitant inactivation of p53 and Chk2 in breast cancer
-
Sullivan A., Yuille M., Repellin C., Reddy A., Reelfs O., Bell A., Dunne B., Gusterson B.A., Osin P., Farrell P.J., Yulug I., Evans A., Ozcelik T., Gasco M., and Crook T. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21 (2002) 1316-1324
-
(2002)
Oncogene
, vol.21
, pp. 1316-1324
-
-
Sullivan, A.1
Yuille, M.2
Repellin, C.3
Reddy, A.4
Reelfs, O.5
Bell, A.6
Dunne, B.7
Gusterson, B.A.8
Osin, P.9
Farrell, P.J.10
Yulug, I.11
Evans, A.12
Ozcelik, T.13
Gasco, M.14
Crook, T.15
-
50
-
-
33845780616
-
Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers
-
Williams L.H., Choong D., Johnson S.A., and Campbell I.G. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin. Cancer Res. 12 (2006) 6967-6972
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 6967-6972
-
-
Williams, L.H.1
Choong, D.2
Johnson, S.A.3
Campbell, I.G.4
-
51
-
-
34249803226
-
LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro
-
Huang T.S., Myklebust L.M., Kjarland E., Gjertsen B.T., Pendino F., Bruserud O., Doskeland S.O., and Lillehaug J.R. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol. Cancer 6 (2007) 31
-
(2007)
Mol. Cancer
, vol.6
, pp. 31
-
-
Huang, T.S.1
Myklebust, L.M.2
Kjarland, E.3
Gjertsen, B.T.4
Pendino, F.5
Bruserud, O.6
Doskeland, S.O.7
Lillehaug, J.R.8
-
52
-
-
19344374275
-
RIP3 beta and RIP3 gamma, two novel splice variants of receptor-interacting protein 3 (RIP3), downregulate RIP3-induced apoptosis
-
Yang Y., Hu W., Feng S., Ma J., and Wu M. RIP3 beta and RIP3 gamma, two novel splice variants of receptor-interacting protein 3 (RIP3), downregulate RIP3-induced apoptosis. Biochem. Biophys. Res. Commun. 332 (2005) 181-187
-
(2005)
Biochem. Biophys. Res. Commun.
, vol.332
, pp. 181-187
-
-
Yang, Y.1
Hu, W.2
Feng, S.3
Ma, J.4
Wu, M.5
-
53
-
-
0036791130
-
A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma
-
van Doorn R., Dijkman R., Vermeer M.H., Starink T.M., Willemze R., and Tensen C.P. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res. 62 (2002) 5389-5392
-
(2002)
Cancer Res.
, vol.62
, pp. 5389-5392
-
-
van Doorn, R.1
Dijkman, R.2
Vermeer, M.H.3
Starink, T.M.4
Willemze, R.5
Tensen, C.P.6
-
55
-
-
0037073737
-
Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation
-
Ahn J., and Prives C. Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation. J. Biol. Chem. 277 (2002) 48418-48426
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 48418-48426
-
-
Ahn, J.1
Prives, C.2
-
56
-
-
0036132065
-
Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors
-
Miller C.W., Ikezoe T., Krug U., Hofmann W.K., Tavor S., Vegesna V., Tsukasaki K., Takeuchi S., and Koeffler H.P. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 33 (2002) 17-21
-
(2002)
Genes Chromosomes Cancer
, vol.33
, pp. 17-21
-
-
Miller, C.W.1
Ikezoe, T.2
Krug, U.3
Hofmann, W.K.4
Tavor, S.5
Vegesna, V.6
Tsukasaki, K.7
Takeuchi, S.8
Koeffler, H.P.9
-
57
-
-
34247552376
-
Mutation analysis of the CHK2 gene in breast carcinoma and other cancers
-
Ingvarsson S., Sigbjornsdottir B.I., Huiping C., Hafsteinsdottir S.H., Ragnarsson G., Barkardottir R.B., Arason A., Egilsson V., and Bergthorsson J.T. Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res. 4 (2002) R4
-
(2002)
Breast Cancer Res.
, vol.4
-
-
Ingvarsson, S.1
Sigbjornsdottir, B.I.2
Huiping, C.3
Hafsteinsdottir, S.H.4
Ragnarsson, G.5
Barkardottir, R.B.6
Arason, A.7
Egilsson, V.8
Bergthorsson, J.T.9
-
58
-
-
0038418869
-
Chk1 and Chk2 kinases in checkpoint control and cancer
-
Bartek J., and Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cells 3 (2003) 421-429
-
(2003)
Cancer Cells
, vol.3
, pp. 421-429
-
-
Bartek, J.1
Lukas, J.2
|